Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metastatic breast cancer
Phase of Trial: Phase IV
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms ESEMPiO; PAINTER
- 03 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 29 Sep 2015 Interim results of of 623 patients with updated data up to March 2015 was presented at the European Cancer Congress 2015.
- 14 Sep 2015 According to an Eisai media release, data from this study will be presented at the 18th Biennial Congress of European Cancer Congress (ECC).